Table 5.
Overview of 90-daymRS scores and functional independence tendencies in cancer patients compared to non-cancer patients.
| Author, Year | 90D MRS | 90D FI |
|---|---|---|
| Cho et al., 2020 [10] | NA | - |
| Ciolli et al., 2021 [11] | NA | - |
| Jeon et al., 2021 [19] | ↓ * | ↓ * |
| Joshi et al., 2021 [6] | - | - |
| Jung et al., 2018 [12] | NA | ↓ |
| Mattingly et al., 2022 [8] | ↓ | - |
| Merlino et al., 2021 [15] ** | NA | - |
| Lee et al., 2019 [13] | ↓ | ↓ |
| Lee et al., 2021 [14] | ↓ | ↓ |
| Ozaki et al., 2021 [16] | - | ↓ |
| Sallustio et al., 2019 [17] | NA | - |
| Verschoof et al., 2022 [23] | ↓ | ↓ |
| Yoo et al., 2021 [18] | ↓ | - |
Note: -: No significant difference.↓: Decreased in cancer patients. NA: Not assessed/applicable. * Study did not compare CP and NCP, increased based on respective NCP metrics of other similar studies. ** Study compared functional dependency, defined as mRS 3–5, FI rates deducted from the available data.